BioCorRx (BICX) Long-Term Deferred Tax (2012 - 2025)

BioCorRx's Long-Term Deferred Tax history runs 12 years deep, the most recent figure standing at $13.2 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax rose 6.66% year-over-year to $13.2 million; the TTM figure through Dec 2025 stood at $13.2 million (up 6.66% YoY), while the FY2025 annual figure was $13.2 million, up 6.66% from the prior year.
• Long-Term Deferred Tax came in at $13.2 million for Q4 2025 at BioCorRx, up from $12.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $13.2 million in Q4 2025 to a low of $9.4 million in Q4 2021.
• A 3-year average of $11.6 million and a median of $12.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 40.7% in 2021 and climbed 6.66% in 2025, its largest moves.
• BioCorRx's Long-Term Deferred Tax stood at $9.4 million in 2021, then jumped by 31.86% to $12.3 million in 2024, then advanced by 6.66% to $13.2 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $13.2 million, $12.3 million, and $9.4 million for Q4 2025, Q4 2024, and Q4 2021 respectively.

Peer Comparison